310 citations
,
November 2011 in “Environment International” This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.
38 citations
,
February 2023 in “International Journal of Advanced Research in Science Communication and Technology” This article reviews plant-based secondary metabolites with potential anticancer properties and highlights the need for new treatments due to the side effects of current cancer therapies, but it provides no clinical results.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
11 citations
,
October 2019 in “Cancers” This study found that spironolactone enhanced the effectiveness of non-DNA-damaging cancer drugs gemcitabine and osimertinib in cancer cell lines and a mouse xenograft model, likely by suppressing the anti-apoptotic protein survivin.